| GTO ID | GTC2893 |
| Trial ID | NCT05194735 |
| Disease | Gynecologic Cancer | Colorectal Cancer | Pancreatic Cancer | Non-Small Cell Lung Cancer | Cholangiocarcinoma | Ovarian Cancer | Endometrial Cancer | Squamous Cell Lung Cancer |
| Altered gene | Neoantigen |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | Neoantigen TCR-T cells |
| HLA | HLA-A*11:01|HLA-C*08:02|HLA-C*01:02|HLA-A*02:01|HLA-DRB1*13:01|HLA-A*68:01|HLA-DRB3*02:02|HLA-DPA1*02:01|HLA-DPB1*01:01 |
| Phase | Phase1|Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | Phase I/II Study of Autologous T Cells Engineered Using the Sleeping Beauty System to Express T-Cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects With Solid Tumors |
| Year | 2022 |
| Country | United States |
| Company sponsor | Alaunos Therapeutics |
| Other ID(s) | TCR001-201 |
| Cohort 1 | |||||||||||
|
|||||||||||